MedTrace Logo

Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries

NCT01754688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 624

Last updated 2019-01-25

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that a new BIND (Bilirubin Induced Neurologic Dysfunction) scoring method adapted for the developing world (BIND II, developed by our team for use by health care workers), with additional modifications for community use (the community BIND, C-BIND), will improve the ability to identify infants with ABE and to distinguish ABE from other common causes of neonatal morbidity and mortality compared to currently available survey tools.

Conditions

  • Hyperbilirubinemic Encephalopathy

Sponsors & Collaborators

Principal Investigators

  • Tina Slusher, MD · University of Minnesota

Eligibility

Max Age
14 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Nigeria

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01754688 on ClinicalTrials.gov